11.3 USP <800> Hazardous Drug Handling & Safety Protections

11.3 USP <800> Hazardous Drug Handling & Safety Protections

Healthcare workers who handle hazardous drugs (HDs)—such as antineoplastic agents, immunosuppressants, antiviral compounds, and hormonal therapies—face substantial occupational health risks. Chronic low-level occupational exposure through dermal contact, aerosol inhalation, accidental ingestion, or needle-stick injuries has been documented to cause chromosomal damage, secondary malignancies, bone marrow suppression, reproductive failure, and congenital anomalies.

To safeguard healthcare personnel and environmental integrity, the United States Pharmacopeia promulgated General Chapter <800> (Hazardous Drugs – Handling in Healthcare Settings). In New Jersey, USP <800> standards are enforced across all retail, institutional, and ambulatory pharmacy practice sites under N.J.A.C. 13:39-11, operating in concert with criteria established by the National Institute for Occupational Safety and Health (NIOSH) and the Occupational Safety and Health Administration (OSHA).

---

Hazardous Drug Identification & NIOSH Toxicological Criteria

USP <800> applies to all personnel who handle HD preparations—including pharmacists, pharmacy technicians, nurses, physicians, receiving dock personnel, and environmental services staff—and encompasses all stages of the medication supply chain: receipt, storage, compounding, dispensing, transport, administration, and disposal.

The Six NIOSH Toxicological Criteria

A chemical entity is classified as a hazardous drug if studies in animals or humans demonstrate that the drug exhibits at least one of the following six toxicological criteria established by NIOSH:

1. Carcinogenicity: Ability of the agent to induce cancer or increase the incidence of tumors;
2. Teratogenicity or Developmental Toxicity: Potential to cause embryonic lethality, malformations, or structural abnormalities in developing fetuses;
3. Reproductive Toxicity: Impairment of male or female fertility, menstrual dysfunction, or adverse pregnancy outcomes;
4. Organ Toxicity at Low Doses: Ability to induce severe target-organ damage (e.g., cardiotoxicity, nephrotoxicity, hepatotoxicity, pulmonary fibrosis) at low therapeutic doses (≤ 10 mg/day or ≤ 1 mg/kg/day in animal or human models);
5. Genotoxicity: Mutagenic potential to cause DNA strand breaks, mutations, or chromosomal aberrations;
6. Structure and Toxicity Mimicry: New drugs that exhibit chemical structures or toxicity profiles closely mimicking existing hazardous agents.

                                    NIOSH List Groups
                                           │
         ┌─────────────────────────────────┼─────────────────────────────────┐
         ▼                                 ▼                                 ▼
      Group 1                           Group 2                           Group 3
Antineoplastic Drugs              Non-Antineoplastic HDs            Reproductive Risk Only
• Cisplatin, cyclophosphamide     • Cyclosporine, azathioprine      • Finasteride, dutasteride
• Fluorouracil, methotrexate      • Carbamazepine, spironolactone   • Warfarin, misoprostol
• Doxorubicin, vincristine        • Topiramate, leflunomide         • Clonazepam, fluconazole

Entity Assessment of Risk (AoR)

Under USP <800>, a healthcare entity may perform a documented Assessment of Risk (AoR) for dosage forms that do NOT require manipulation other than counting or packaging (e.g., dispensing intact commercial antineoplastic tablets or counting intact capsules from a manufacturer stock bottle). If the AoR demonstrates adequate containment through standard operating procedures (e.g., using dedicated counting trays and spatulas that are decontaminated after each use), the entity may adopt alternative containment strategies without full cleanroom secondary engineering controls.

[!CRITICAL] Non-Exempt Formulations: An Assessment of Risk can NEVER exempt active pharmaceutical ingredients (APIs) in powder form, or any hazardous drug that must be manipulated through crushing, dissolving, pouring, or sterile reconstitution. All such preparations must strictly follow full USP <800> engineering containment controls.

---

Containment Engineering Controls: C-PEC, C-SEC & Negative Pressure Specs

Handling hazardous drugs requires specialized engineering controls designed to prevent both cross-contamination of products and environmental exposure of personnel.

                             Hazardous Cleanroom Suite Pressures
                             
    Unclassified Area                 ISO Class 7 Anteroom                 ISO Class 7 C-SEC
   [ General Pharmacy ]            [ Hand Hygiene & Garbing ]          [ Containment Buffer Room ]
      Ambient Air         ───►           POSITIVE             ◄───            NEGATIVE
   (Baseline Pressure)              Pressure relative to               Pressure: -0.010" to -0.030"
                                      general hallway                 (Air Changes: ≥30 ACPH)
                                                                                │
                                                                                ▼
                                                                       ISO Class 5 C-PEC
                                                                     [ Class II BSC / CACI ]
                                                                      100% EXTERNALLY VENTED

Containment Primary Engineering Controls (C-PECs)

The C-PEC is the ventilated enclosure designed to minimize worker exposure while maintaining aseptic conditions:

• Sterile HD Compounding: Must use a Class II Biological Safety Cabinet (BSC) (Type A2 externally vented, Type B1, or Type B2 total exhaust) or a Compounding Aseptic Containment Isolator (CACI).
  • Must maintain ISO Class 5 unidirectional downward laminar airflow.
  • Must be 100% externally vented through dedicated ductwork to the outside of the building. Recirculation of exhaust air into the buffer room or general pharmacy is strictly prohibited.
• Non-Sterile HD Compounding: Must use a Containment Ventilated Enclosure (CVE), a Class I BSC, or a Class II BSC. Must be externally vented (redundant HEPA filters in series are permitted only where local exterior venting is physically unfeasible, though external venting remains standard).

Containment Secondary Engineering Controls (C-SECs)

The C-SEC is the dedicated room housing the C-PEC:

• Negative Differential Pressure: The C-SEC buffer room must be maintained under continuous negative pressure between -0.010 and -0.030 inches water column (-2.5 Pa to -7.5 Pa) relative to all adjacent areas. This pressure gradient guarantees that air flows inward, containing all airborne chemical vapors and aerosols within the room.
• Air Changes Per Hour (ACPH):
  • Sterile HD Buffer Room: Minimum 30 ACPH of externally vented HEPA-filtered air;
  • Non-Sterile HD Compounding Room: Minimum 12 ACPH;
  • Dedicated HD Storage Room: Minimum 12 ACPH.
• Anteroom Requirements for Sterile HD Suites: Anteroom must maintain ISO Class 7 air quality with a minimum of 30 ACPH. The anteroom must be positive relative to the general pharmacy hallway, while the negative-pressure buffer room is maintained negative relative to the anteroom.

---

Hazardous Drug Storage & Receipt Standards

USP <800> mandates strict separation of hazardous drug inventory to prevent contamination of conventional stock:

• Unpacking Protocol: Hazardous drugs must be unpacked in an area that is neutral or under negative pressure. Unpacking must NEVER occur in sterile compounding areas or positive-pressure cleanroom spaces.
• Dedicated HD Storage Room: Antineoplastic HDs requiring manipulation and all hazardous active pharmaceutical ingredients (APIs) must be stored in a dedicated room that is:
  • Physically separate from non-hazardous drug stock;
  • Maintained under negative pressure (-0.010 to -0.030 inches w.c.);
  • Externally ventilated with at least 12 air changes per hour (12 ACPH).
• Prohibition Against Floor Storage: Hazardous drugs must never be stored on the floor. Shelving units must have lip barriers or raised edges to prevent drug containers from falling and breaking during seismic or accidental impact.
• Dedicated Refrigeration: Hazardous drugs requiring refrigeration must be stored in a dedicated, standalone refrigerator located within a negative-pressure storage room with at least 12 ACPH. The refrigerator cannot be shared with non-hazardous medications.

---

Personal Protective Equipment (PPE) & Closed-System Drug-Transfer Devices (CSTDs)

Personal Protective Equipment acts as the final operational shield protecting healthcare personnel from chemical absorption and contact.

Chemotherapy Gloves

• Must be tested and certified compliant with ASTM Standard D6978 (tested against a battery of chemotherapy agents for permeation resistance).
• Must be powder-free, as glove powder absorbs chemical residue and disperses it into the air.
• Two Pairs Required: Personnel must wear two pairs of chemotherapy gloves for compounding sterile and non-sterile HDs, handling spills, and administering hazardous drugs.
• Cuff Placement: The inner glove is worn under the gown sleeve cuff; the outer glove is pulled over the gown cuff.
• Glove Change Interval: Outer gloves must be inspected prior to use and changed at least every 30 minutes during continuous compounding, or immediately if torn, punctured, or contaminated.

Chemotherapy Gown

• Must be disposable and constructed of non-linting, non-absorbent material coated with polyethylene or laminate film.
• Must feature a solid front (back-closing), long sleeves, and tight-fitting elastic or knit cuffs.
• Must be changed every 2 to 3 hours during compounding, or immediately following a spill, splash, or known contamination.
• Gowns worn in the C-SEC must be discarded in yellow trace-chemotherapy waste containers prior to leaving the hazardous compounding area; they must never be reworn or worn outside the C-SEC.

Respiratory Protection

• A fit-tested, NIOSH-approved N95 respirator provides protection against airborne particulate matter and aerosols, but does NOT protect against hazardous chemical vapors or gases.
• For scenarios involving hazardous drug gas/vapor exposure, cleaning large spills, or decontaminating the work tray beneath a BSC work surface, personnel must wear a Powered Air-Purifying Respirator (PAPR) or a full-face chemical cartridge respirator.
• Standard surgical masks provide zero respiratory protection against HD aerosols and cannot be used as respiratory PPE.

Eye and Face Protection

• Goggles and a full face shield must be worn when there is a hazard of aerosolization or splashing (e.g., cleaning up spills, opening glass ampules, or working outside a C-PEC).
• Regular eyeglasses or safety glasses with side shields are completely inadequate to protect against chemical splashes and vapors.

Closed-System Drug-Transfer Devices (CSTDs)

A Closed-System Drug-Transfer Device is a drug-transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system.

• CSTD Mechanism: Utilizes double-membrane dry connections or internal pressure-equalizing filtration chambers to seal the vial-syringe-tubing pathway.
• The Compounding vs. Administration Mandate:
  • During Compounding: CSTDs are recommended by USP <800> inside the C-PEC.
  • During Administration: CSTDs are STATUTORILY MANDATORY under USP <800> for the administration of antineoplastic hazardous drugs when the dosage form allows.

                                  CSTD Regulatory Mandate
                                             │
             ┌───────────────────────────────┴───────────────────────────────┐
             ▼                                                               ▼
     During Compounding                                             During Administration
• Recommended by USP <800>                                     • STATUTORILY MANDATORY
• Operates within ISO 5 C-PEC                                  • Protects bedside nursing personnel
• Prohibits vapor escape & coring                              • Mandatory for all antineoplastics
                                                                 when dosage form allows

---

Deactivation, Decontamination, Cleaning & Disinfection Protocol

Maintaining containment in hazardous drug environments requires a four-step chemical cleaning process. Cleaning an HD work area with alcohol alone is a dangerous compliance violation that spreads, rather than removes, chemical residue.

[!WARNING] Bleach Corrosion Neutralization: Sodium hypochlorite (bleach) is a potent deactivating oxidizer, but it corrodes stainless steel BSC surfaces. Whenever bleach is used for deactivation, personnel must immediately follow with sterile water or sodium thiosulfate to neutralize and remove the oxidizing agent, followed by sterile 70% IPA.

---

Spill Management, Exposure Protocols & OSHA 30-Year Record Retention

Hazardous Drug Spill Kits

Spill kits must be prominently labeled, pre-packaged, and immediately accessible in all areas where HDs are received, stored, compounded, transported, or administered. Spill kits contain: chemo-absorbent pads, spill control pillows, neutralizing agents, disposable plastic scoops/scrapers, two pairs of chemotherapy gloves, a chemotherapy gown, goggles, an N95 respirator, and thick, puncture-resistant yellow chemotherapy waste bags.

Acute Exposure Decontamination Protocol

If a healthcare worker experiences direct skin or eye contact with a hazardous drug:

1. Immediately remove contaminated PPE and clothing;
2. Clean the affected skin area thoroughly with warm water and soap for at least 15 minutes;
3. For eye splashes, immediately flush the eyes at an emergency eyewash station for at least 15 minutes with continuous saline or potable water;
4. Report the incident immediately to the Pharmacist-in-Charge, employee health, and safety officer;
5. Document the drug name, lot number, estimated volume, and exposure circumstances in the facility's incident log.

OSHA 30-Year Medical Surveillance Record Retention Mandate

Under the Occupational Safety and Health Administration (OSHA) Standard 29 CFR 1910.1020 (Access to Employee Exposure and Medical Records):

• Every healthcare facility handling hazardous drugs must maintain a formal Medical Surveillance Program to track baseline health, reproductive history, and potential occupational toxicities of exposed personnel.
• All medical records, baseline laboratory profiles, physical examination reports, and documentation of acute accidental exposures must be retained for the duration of the worker's employment PLUS thirty (30) years.
• Under New Jersey law (N.J.A.C. 13:39-11), routine facility compounding records, standard operating procedures, and training logs are retained for 5 years, but any OSHA-governed employee medical surveillance and exposure logs must be preserved under the federal 30-year standard.